Aldon, Yoann

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 1,140

Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA

Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 206

Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA

Blakney, A. K., McKay, P. F., Christensen, D., Yus, B. I., Aldon, Y., Follmann, F., & Shattock, R. J. (2019) · Journal of Controlled Release

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 48